What Happened? ...LLY) jumped 15.3% in the morning session after results from a Phase 3 trial showed that its experimental drug, Orforglipron, performed significantly well in helping patients manage obesity and diabetes ... .
With Q4 behind us, let’s have a look at Eli Lilly (NYSE. LLY) and its peers ... LLY) ... LLY) discovers, develops, and manufactures pharmaceutical products for conditions including diabetes, obesity, cancer, immunological disorders, and neurological diseases.